So, get you understand how we see that. So, not alone, but real partnership and while the chemical or the technical part that we have or are mastering well, we don’t see any limitation so far, not at all. At the same time, the complexity of the value generation chain, yes, and that’s where we want to team up. And that’s why you should see, hopefully, the collaboration agreements this year. Then I think the funding let’s go back to that an acceleration, I think it’s true. So, what we have at the cash reach is built on, let’s call it, scenario €“ on a conservative scenario of a rather steady cash burn. And if a program is stopped obviously then the cash burn will be longer, which is in a way not good, if things go really well, if 533 looks great, then we want to accelerate, you are right.
Then also our cash burn would have to change. At that point in time, but also our stock price should change, so there is different optionalities there or partnerships. So, to do a partnership or whatever on good data is a totally different game than now. So for us, it’s really bringing the good programs forward, collecting the data and then see what is the best way to bring it forward alone or in partnerships. 533 is the base that we want to do it alone and if that is possible, that is plan A. I hope that answers part of your funding question. We have not grown massively last year. We did not give the exact FTE numbers. We also don’t plan to grow massively this year. So, we see this rather steady, a bit up and down. We just need the resources that €“ to progress the pipeline.
I think we are at this point in time more on a steady state than a growth trajectory, also given the market and the state of the company €“ stage of the company where the programs are. I hope we could answer your questions, Joe.
Joe Walton: Yes. Thank you. You have given us your FTEs, You increased your staff by 7% on Page 14, but thank you very much.
Patrick Amstutz: Yes. But what that’s going to be next year, if it is €“ I mean, 7% is more or less almost equal. It depends really how things develop, yes.
Joe Walton: Thank you.
Operator: The next question comes from Georgi Yordanov with TD Cowen. Please go ahead.
Georgi Yordanov: Hey guys. Thank you so much for taking our questions and congratulations on the progress. So, maybe on the topic of durability for 533, maybe can you, I guess talk about when can we expect some initial insight into that? And then maybe also, what have you seen from your preclinical data in that respect in terms of €“ are you seeing certain like mechanisms of resistance that evolve over time? How should we be thinking what does the data suggest? And then on the radioligand therapy, maybe can you just talk about how you made the decision to select the tumor-specific antigen here? We have seen other companies go after targets like mono . So, maybe can you just talk about how do you decide to €“ why did you decide to take a slightly different approach? And what do you think is differentiated by the DARPin platform that that could allow you to have differentiation on that market?